Citicoline ECS Delivery for Stroke Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering citicoline (CDPC) to treat stroke are ineffective due to the blood-brain barrier, leading to unsatisfactory treatment outcomes and increased adverse effects, as conventional oral or intravenous delivery methods struggle to reach the brain, and the polarity of the CDPC molecule hinders its permeation.
Innovation Solution
Administering CDPC via the brain extracellular space at concentrations of 40 mmol/L-60 mmol/L, specifically 50 mmol/L, with a flow rate of 0.2 μL/min and a dose of 2 μL, targeting the caudate nucleus, to enhance brain penetration and reduce dosage while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oral or intravenous delivery methods are used to administer CDPC, then the drug can be delivered systemically, but the treatment effectiveness is unsatisfactory due to the blood-brain barrier blocking CDPC from reaching the brain
Solution Approach 1:
The patent uses the brain extracellular space (ECS) as an intermediary pathway to deliver CDPC directly to the brain tissue, bypassing the blood-brain barrier. The ECS serves as a mediating route that allows small molecule drugs like CDPC to reach their target without being blocked by the BBB, thus improving treatment effectiveness while avoiding the harmful blocking effect.
Solution Approach 2:
The patent transitions from conventional systemic delivery (oral/intravenous) to direct intracranial delivery through the ECS. This represents a dimensional change in the delivery pathway - moving from the systemic circulation dimension to the brain interstitial space dimension, allowing the drug to reach the brain parenchyma directly and overcome the BBB obstacle.
2Quantity of substance
If the dosage of CDPC is increased to improve brain tissue concentration, then the drug can overcome poor permeation, but adverse effects such as intracranial bleeding increase
Solution Approach 1:
The patent applies local quality by delivering CDPC directly to the brain extracellular space at the site of ischemic injury. This localized delivery ensures high drug concentration precisely where needed (in the affected brain tissue) without requiring systemic high dosages, thereby achieving therapeutic effect while minimizing adverse effects that would occur with whole-body high concentration exposure.
Solution Approach 2:
The patent changes the delivery parameters from systemic administration to direct ECS injection with optimized concentration (40-60 mmol/L) and flow rate (0.2 μL/min). By adjusting these parameters locally at the injection site, the patent achieves sufficient brain tissue concentration for therapy while avoiding the adverse effects associated with higher systemic dosages.
3Ease of operation
If conventional delivery methods are used, then the administration is simple, but the drug cannot reach the lesion in cerebral ischemic stroke where local blood flow decreases or stops
Solution Approach 1:
The patent uses the brain extracellular space as an intermediary delivery route that is independent of the compromised cerebral blood flow. By injecting CDPC directly into the ECS, the drug bypasses the blocked or reduced blood vessels and reaches the ischemic lesion through the interstitial fluid pathway, ensuring reliable delivery even when conventional vascular routes fail.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly reduces cerebral infarction size and improves treatment efficacy for stroke, with a suitable concentration of 50 mM showing the best results, lowering the risk of adverse effects such as intracranial bleeding, and allowing for a lower dosage compared to conventional delivery methods.
Implementation Method 1
His work focused on macromolecular drugs which are driven by pressure, then diffused in the ECS and distributed to the target region of the brain
Data Source
AI summary
The present invention provides administration methods for CDPC for treating stroke. CDPC was delivered via ECS at a concentration of 40 mmol/L-60 mmol/L. In a specific embodiment of the present invention, the concentration of CDPC administered is 50 mmol/L, CDPC is delivered at one time, the flow rate of administration is 0.2 μL/min, the volume of CDPC is 1.33 μL/mL of brain tissue, and the CDPC is administered in the caudate nucleus. The method can decrease the concentration of CDPC entering the brain and further decrease the dosage while improving efficacy. Thus, the result is improved and the probability of adverse effects due to the drug is reduced.